These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25826890)

  • 21. Strontium as therapy for osteoporosis.
    Marie PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate in post-menopausal osteoporosis.
    Przedlacki J
    Endokrynol Pol; 2011; 62(1):65-72. PubMed ID: 21365582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E; Chabadel A; Saltel F; Jurdic P
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Strontium ranelate in post-menopausal osteoporosis].
    Przedlacki J
    Endokrynol Pol; 2011; 62 Suppl 2():23-31. PubMed ID: 22125019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
    Thomsen JS; Straarup TS; Danielsen CC; Oxlund H; Brüel A
    Scand J Rheumatol; 2013; 42(5):408-16. PubMed ID: 23527881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
    Shiraki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
    Namazi H
    Curr Med Res Opin; 2012 Apr; 28(4):609; author reply 609-10. PubMed ID: 22435797
    [No Abstract]   [Full Text] [Related]  

  • 28. [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].
    Korsić M; Giljević Z; Kastelan D
    Lijec Vjesn; 2006; 128(5-6):180-2. PubMed ID: 16910420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strontium ranelate improves bone microarchitecture in osteoporosis.
    Hamdy NA
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv9-13. PubMed ID: 19783592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different doses of strontium ranelate and mechanical vibration modulate distinct responses in the articular cartilage of ovariectomized rats.
    Mierzwa AGH; Campos JF; Jesus MF; Nader HB; Lazaretti-Castro M; Reginato RD
    Osteoarthritis Cartilage; 2017 Jul; 25(7):1179-1188. PubMed ID: 28223125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting subchondral bone for treating osteoarthritis: what is the evidence?
    Kwan Tat S; Lajeunesse D; Pelletier JP; Martel-Pelletier J
    Best Pract Res Clin Rheumatol; 2010 Feb; 24(1):51-70. PubMed ID: 20129200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An OA phenotype may obtain major benefit from bone-acting agents.
    Roman-Blas JA; Castañeda S; Largo R; Lems WF; Herrero-Beaumont G
    Semin Arthritis Rheum; 2014 Feb; 43(4):421-8. PubMed ID: 24016748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure.
    Busse B; Jobke B; Hahn M; Priemel M; Niecke M; Seitz S; Zustin J; Semler J; Amling M
    Acta Biomater; 2010 Dec; 6(12):4513-21. PubMed ID: 20654744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease.
    Strassle BW; Mark L; Leventhal L; Piesla MJ; Jian Li X; Kennedy JD; Glasson SS; Whiteside GT
    Osteoarthritis Cartilage; 2010 Oct; 18(10):1319-28. PubMed ID: 20633675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.
    Li C; Paris O; Siegel S; Roschger P; Paschalis EP; Klaushofer K; Fratzl P
    J Bone Miner Res; 2010 May; 25(5):968-75. PubMed ID: 19874195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The action of Strontium ranelate: myth or reality.
    Bunyaratavej N
    J Med Assoc Thai; 2011 Oct; 94 Suppl 5():S35-7. PubMed ID: 22338924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in bone strength parameters. The role of strontium ranelate.
    Tournis S
    J Musculoskelet Neuronal Interact; 2007; 7(3):266-7. PubMed ID: 17947810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
    Marie PJ
    Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should subchondral bone turnover be targeted when treating osteoarthritis?
    Karsdal MA; Leeming DJ; Dam EB; Henriksen K; Alexandersen P; Pastoureau P; Altman RD; Christiansen C
    Osteoarthritis Cartilage; 2008 Jun; 16(6):638-46. PubMed ID: 18362080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.